Classic Congenital Adrenal Hyperplasia research hub
5 indexed studies · 5 currently recruiting
- recruitingTherapeutic exploratory (Phase II)
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Reducing Supraphysiologic Glucocorticoid Use in Adult Subjects with Classic Congenital Adrenal Hyperplasia
This study is looking into a new medication called Tildacerfont for adults with a condition called classic congenital adrenal hyperplasia. It aims to see if Tildacerfont can help reduce the amount of steroid medicine (like hydrocortisone or prednisolone) people need to take.
Sweden · Netherlands · Denmark - recruitingTherapeutic exploratory (Phase II)
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Adult Subjects with Classic Congenital Adrenal Hyperplasia
This study is testing a new medicine, Tildacerfont, for adults with a condition called Classic Congenital Adrenal Hyperplasia (CAH). Doctors want to see if it helps reduce certain hormone levels and if it's safe to use.
Sweden · Netherlands · Ireland - recruitingPHASE2, PHASE3
A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)
This study is looking into a new medication called atumelnant for children and teenagers with a condition called Congenital Adrenal Hyperplasia (CAH). It wants to see if the medication is safe, works well, and how the body handles it.
United States · Argentina · Australia - recruitingPHASE3
A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia
This study is testing a new medicine, atumelnant, for adults with a condition called congenital adrenal hyperplasia (CAH). It aims to see if the medicine is safe, works well, and how the body handles it.
United States · Argentina · Australia - recruitingPHASE2
An Extension Study to Evaluate Safety and Efficacy of Atumelnant in Participants With Congenital Adrenal Hyperplasia
This study looks at the long-term safety and effectiveness of a new medicine, atumelnant, for people with Congenital Adrenal Hyperplasia (CAH). It's for those who have already tried atumelnant in a previous study and could benefit from continuing it.
United States · Argentina · Brazil